Sustained release ranolazine formulations
US6617328B2 · kind B2 · utility
9Cited by
8References
33Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 27, 2002 |
| Grant date | Sep 9, 2003 |
| Priority date | — |
| Expiry date | Sep 27, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.